Answers are grounded in this paper and cite their sources.
Retrospective study found dupilumab improved pruritus and provided safety in older adults, suggesting treatment strategies may enhance care.
In this retrospective real-world study of older adults with long-standing, treatment-refractory immunological eruption of aging, dupilumab was associated with rapid, substantial, and sustained improvement in pruritus with a favorable safety profile. Most patients exhibited Th2-skewed immunologic features, including elevated IgE levels, low vitamin D, and dermal eosinophilia, supporting a potential role of Th2-driven immunosenescence in disease pathogenesis. Although baseline immunologic abnormalities were associated with more rapid early improvement, larger prospective studies are needed to validate predictive biomarkers and establish standardized treatment strategies for IEA.
No takes yet. Share an insight, caveat, or question.
Baek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: